COMPANY

Mahzi Therapeutics

Profile checked Oct 10, 2026

Keywords: Pitt Hopkins Syndrome MZ-1866

Timeline

Dec 19, 2025 Trial start 1: Phase 1/2 Study of MZ-1866, an AAV-9 Gene Therapy Delivered by Intracerebroventricular Injection to Participants With Pitt Hopkins Syndrome source ↗

2029-03 (ESTIMATED) · 1 · Phase 1/2 Study of MZ-1866, an AAV-9 Gene Therapy Delivered by Intracerebroventricular Injection to Participants With Pitt Hopkins Syndrome · NCT07135050

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT07135050	Phase 1/2 Study of MZ-1866, an AAV-9 Gene Therapy Delivered by Intracerebroventricular Injection to Participants With Pitt Hopkins Syndrome	1	Recruiting	Dec 19, 2025	2029-03 (estimated)